- RecruitingPHASE1, PHASE2
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This study is testing a new medicine, WEF-001, for people with advanced cancers that have a specific genetic change called a 'KRAS mutation'. Doctors want to see if it's safe, how the body handles it, and if it could help shrink tumours.
For: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma · Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer · Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung CancerUnited States · Canada · United Kingdom - AuthorisedPhase I and Phase II (Integrated)- Other
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of WEF-001 in participants with Advanced KRAS- Mutant Solid Tumours.
This study is testing a new medicine called WEF-001 for people with advanced cancers that have a specific genetic change called KRAS mutation. It's looking to see if the medicine is safe, what effects it has on the body, and if it can shrink these tumours.
For: Advanced KRAS- Mutant Solid TumoursSpain